The Kratom Industry Faces Internal Conflict Over Potent 7-OH Extracts

The kratom industry, which once united to successfully fend off a federal ban, is now fracturing over the rise of 7-hydroxymitragynine (7-OH). While traditional kratom advocates promote the plant as a natural, mild alternative to opioids, the emergence of highly concentrated 7-OH products has created a schism. Industry leaders, including the American Kratom Association, argue that these potent extracts are chemically manipulated substances that threaten the legitimacy of the broader kratom market, while proponents of 7-OH maintain that the compound is an essential, natural derivative of the plant.

The conflict is fueled by growing reports of severe withdrawal symptoms and polydrug overdoses associated with 7-OH, which is increasingly sold in gas stations and convenience stores. Unlike traditional kratom, which has a long history of cultural use, 7-OH is a modern, ultra-potent extract that lacks extensive clinical research. Experts warn that these products often contain poorly understood compounds, raising significant public health concerns and inviting the kind of federal scrutiny that the industry has spent years trying to avoid.

This internal "civil war" is further complicated by shifting political winds and conflicting stances from federal officials. With some government figures calling for strict scheduling of 7-OH and others offering confusing endorsements, the regulatory landscape remains volatile. As several states move to implement their own bans, the industry faces an existential crisis: either distance itself from these high-potency extracts to preserve the reputation of traditional kratom or risk being swept up in a broader, more restrictive regulatory crackdown that could jeopardize the entire sector.